CROS NT Announces Further Expansion Into The UK Market
CROS NT is pleased to announce the next phase of its European expansion with the hiring of a new VP and the establishment of a UK office.
CROS NT is starting the new year by announcing its expansion into the United Kingdom. After successfully expanding operations into Germany in 2010 with an office in Augsburg, CROS NT is moving to the UK market with its service offering of superior data management and biostatistics analysis for clinical trials.
Andrew MacGarvey, who joined the company on 3 January 2012, will lead the UK operations. MacGarvey brings considerable experience to CROS NT having spent over 14 years in the pharmaceutical sector. Andrew has worked for Omnicare, PRA International, Datatrial and Quanticate. During his time at both Datatrial and Quanticate, he helped to grow UK-based operations as well as establishing U.S. offices.
"Andrew is the perfect candidate for this role" says Paolo Morelli, CEO of the CROS NT Group, "he has experience at both establishing new operations and growing them. He will launch CROS in the UK, allowing us to provide closer service for our many customers there. I am delighted to welcome Andrew to our leadership team and to add the UK to our existing hubs in Italy and Germany."
"I have followed the activities of CROS NT for some time," says MacGarvey "I am excited by the opportunity to help with the growth of the business. CROS NT are focused on customer care, something that is very important to me. I will be bringing their great service to the UK and ultimately the USA."
About CROS NT Group
CROS NT is a CRO specializing in clinical data management, statistical analysis, eCRF, ePRO and Life Science Application Hosting services. CROS NT was founded in 1992 and successfully implements high quality and modern rapid execution applications of clinical study tasks.
CROS NT service relies on leading technologies, proven processes and employs experts to deliver on every project's requirements with a group of highly qualified project managers and biostatisticians.
CROS NT has completed over 800 studies in a wide range of therapeutic areas like respiratory, oncology, dermatology, cardiovascular, HIV and Infectious diseases for clinical and observational studies. The clients and partners are pharmaceuticals, biotechnology, medical device and academic organizations in Europe and the U.S. The reputation has been built on experience, quality, responsiveness to client needs and a passion to achieve the highest performance.
SOURCE: CROS NT